ペプチド治療薬市場：技術別（混相、液相、固相）、APIタイプ別（CMO、自社）、薬効分類別、用途別、エンドユーザー別-2023-2030年の世界予測

ペプチド治療薬の世界市場は、2023年に334億米ドル、CAGR 11.03%で大きく成長し、2030年には695億6,000万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のペプチド治療薬市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーが特定のニーズに基づいて情報に基づいた意思決定を行えるようにします。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.ペプチド治療薬の世界市場規模および予測は？

2.予測期間中、世界のペプチド治療薬市場を形成するCOVID-19の阻害要因と影響は？

3.ペプチド治療薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.ペプチド治療薬の世界市場における競争戦略は？

5.ペプチド治療薬の世界市場における技術動向と規制の枠組みは？

6.ペプチド治療薬の世界市場における主要ベンダーの市場シェアは？

7.ペプチド治療薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん、心血管障害（CVD）、代謝障害の罹患率の増加
    • 技術の進歩と新しいペプチドへの研究開発投資
  • 抑制要因
    • 天然ペプチドは化学的および物理的安定性が低く、循環血漿半減期が短い
  • 機会
    • 強力な製品パイプラインポートフォリオの存在
    • 次世代タンパク質やペプチド治療薬を開発する新プラットフォームの採用
  • 課題
    • 厳しい安全規制の存在
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 ペプチド治療薬市場：技術別

• ハイブリッドフェーズ
• 液相
• 固相

第7章 ペプチド治療薬市場APIタイプ別

• CMO
• 社内

第8章 ペプチド治療薬市場薬物クラス別

• カルシトニン
• グルカゴンと類似体
• インスリン
• 黄体形成ホルモン放出ホルモン
• ソマトスタチン
• バソプレシン

第9章 ペプチド治療薬市場：用途別

• 抗感染症
• がん
• 心血管疾患呼吸器疾患
• 中枢神経系
• 皮膚科
• 胃腸
• 代謝
• 腎臓

第10章 ペプチド治療薬市場：エンドユーザー別

• 病院
• 製薬産業
• 調査

第11章 南北アメリカのペプチド治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域のペプチド治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのペプチド治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別

第15章 掲載企業一覧

第16章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. PEPTIDE THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. PEPTIDE THERAPEUTICS MARKET SIZE, 2022 VS 2030
• FIGURE 3. PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
• FIGURE 5. PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2022 VS 2030 (%)
• FIGURE 6. PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
• FIGURE 7. PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
• FIGURE 8. PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2022 VS 2030 (%)
• FIGURE 9. PEPTIDE THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 10. PEPTIDE THERAPEUTICS MARKET DYNAMICS
• FIGURE 11. PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 20. PEPTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 21. PEPTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. PEPTIDE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. PEPTIDE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 5. PEPTIDE THERAPEUTICS MARKET SIZE, BY HYBRID PHASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. PEPTIDE THERAPEUTICS MARKET SIZE, BY LIQUID PHASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. PEPTIDE THERAPEUTICS MARKET SIZE, BY SOLID PHASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 9. PEPTIDE THERAPEUTICS MARKET SIZE, BY CMO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. PEPTIDE THERAPEUTICS MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 12. PEPTIDE THERAPEUTICS MARKET SIZE, BY CALCITONINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. PEPTIDE THERAPEUTICS MARKET SIZE, BY GLUCAGON & ANALOGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. PEPTIDE THERAPEUTICS MARKET SIZE, BY INSULINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. PEPTIDE THERAPEUTICS MARKET SIZE, BY LUTEINIZING HORMONE-RELEASING HORMONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. PEPTIDE THERAPEUTICS MARKET SIZE, BY SOMATOSTATINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. PEPTIDE THERAPEUTICS MARKET SIZE, BY VASOPRESSIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 19. PEPTIDE THERAPEUTICS MARKET SIZE, BY ANTI-INFECTIVE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. PEPTIDE THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. PEPTIDE THERAPEUTICS MARKET SIZE, BY CARDIO VASCULAR DISEASE RESPIRATORY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. PEPTIDE THERAPEUTICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. PEPTIDE THERAPEUTICS MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. PEPTIDE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. PEPTIDE THERAPEUTICS MARKET SIZE, BY METABOLIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. PEPTIDE THERAPEUTICS MARKET SIZE, BY RENAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 28. PEPTIDE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. PEPTIDE THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL INDUSTRIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. PEPTIDE THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 47. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 48. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 50. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. CANADA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 75. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 76. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 77. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. CHINA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 80. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 81. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 82. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. INDIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 165. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 166. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 167. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 168. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. ITALY PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 185. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 186. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 187. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 188. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. POLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 190. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 191. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 192. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 193. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 194. QATAR PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY API TYPE, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM PEPTIDE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 240. PEPTIDE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 241. PEPTIDE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 242. PEPTIDE THERAPEUTICS MARKET LICENSE & PRICING

The Global Peptide Therapeutics Market is forecasted to grow significantly, with a projected USD 33.40 billion in 2023 at a CAGR of 11.03% and expected to reach a staggering USD 69.56 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Peptide Therapeutics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Peptide Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Technology, market is studied across Hybrid Phase, Liquid Phase, and Solid Phase. The Solid Phase is projected to witness significant market share during forecast period.

Based on API Type, market is studied across CMO and In-house. The In-house is projected to witness significant market share during forecast period.

Based on Drug Class, market is studied across Calcitonins, Glucagon & Analogs, Insulins, Luteinizing Hormone-Releasing Hormone, Somatostatins, and Vasopressin. The Vasopressin is projected to witness significant market share during forecast period.

Based on Application, market is studied across Anti-infective, Cancer, Cardio Vascular Disease Respiratory, Central Nervous System, Dermatology, Gastrointestinal, Metabolic, and Renal. The Central Nervous System is projected to witness significant market share during forecast period.

Based on End User, market is studied across Hospitals, Pharmaceutical Industries, and Research Laboratories. The Research Laboratories is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 36.39% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Peptide Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Peptide Therapeutics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Peptide Therapeutics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Peptide Therapeutics Market?

4. What is the competitive strategic window for opportunities in the Global Peptide Therapeutics Market?

5. What are the technology trends and regulatory frameworks in the Global Peptide Therapeutics Market?

6. What is the market share of the leading vendors in the Global Peptide Therapeutics Market?

7. What modes and strategic moves are considered suitable for entering the Global Peptide Therapeutics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Peptide Therapeutics Market, by Technology, 2022 vs 2030
• 4.3. Peptide Therapeutics Market, by API Type, 2022 vs 2030
• 4.4. Peptide Therapeutics Market, by Drug Class, 2022 vs 2030
• 4.5. Peptide Therapeutics Market, by Application, 2022 vs 2030
• 4.6. Peptide Therapeutics Market, by End User, 2022 vs 2030
• 4.7. Peptide Therapeutics Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of cancer, cardiovascular disorders (CVDs) and metabolic disorder
    • 5.1.1.2. Technology advancement and R & D investment in new peptides
  • 5.1.2. Restraints
    • 5.1.2.1. Poor chemical and physical stability and a short circulating plasma half-life of naturally occurring peptides
  • 5.1.3. Opportunities
    • 5.1.3.1. Presence of strong product pipeline portfolio
    • 5.1.3.2. Adoption of new platforms that develop next-generation protein or peptide therapeutics
  • 5.1.4. Challenges
    • 5.1.4.1. Presence of stringent safety regulations
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Peptide Therapeutics Market, by Technology

• 6.1. Introduction
• 6.2. Hybrid Phase
• 6.3. Liquid Phase
• 6.4. Solid Phase

7. Peptide Therapeutics Market, by API Type

• 7.1. Introduction
• 7.2. CMO
• 7.3. In-house

8. Peptide Therapeutics Market, by Drug Class

• 8.1. Introduction
• 8.2. Calcitonins
• 8.3. Glucagon & Analogs
• 8.4. Insulins
• 8.5. Luteinizing Hormone-Releasing Hormone
• 8.6. Somatostatins
• 8.7. Vasopressin

9. Peptide Therapeutics Market, by Application

• 9.1. Introduction
• 9.2. Anti-infective
• 9.3. Cancer
• 9.4. Cardio Vascular Disease Respiratory
• 9.5. Central Nervous System
• 9.6. Dermatology
• 9.7. Gastrointestinal
• 9.8. Metabolic
• 9.9. Renal

10. Peptide Therapeutics Market, by End User

• 10.1. Introduction
• 10.2. Hospitals
• 10.3. Pharmaceutical Industries
• 10.4. Research Laboratories

11. Americas Peptide Therapeutics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Peptide Therapeutics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Peptide Therapeutics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. FPNV Positioning Matrix
• 14.2. Market Share Analysis, By Key Player
• 14.3. Competitive Scenario Analysis, By Key Player

15. List of Company Mentioned

16. Appendix

• 16.1. Discussion Guide
• 16.2. License & Pricing